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Summary 
Airways inflammation is thought to play a central role in the pathogenesis of asthma. However, 
the precise role that individual inflammatory cells and mediators play in the development of 
airways hyperreactivity and the morphological changes of the lung during allergic pulmonary 
inflammation is unknown. In this investigation we have used a mouse model of allergic pulmo- 
nary inflammation and interleukin (IL) 5-deficient mice to establish the essential role of this cy- 
tokine and eosinophils in the initiation of aeroallergen-induced lung damage and the develop- 
ment of airways hyperreactivity. Sensitization and aerosol challenge of mice with ovalbumin 
results in airways eosinophilia and extensive lung damage analogous to  that seen in  asthma. 
Aeroallergen-challenged mice also display airways hyperreactivity to [3-methacholine. In IL-5- 
deficient mice, the eosinophilia, lung damage, and airways hyperreactivity normally resulting 
from aeroallergen challenge were abolished, l~econstitution of IL-5 production with recombi- 
nant vaccinia viruses engineered to express this factor completely restored aeroaUergen-induced 
eosinophilia and airways dysfunction. These results indicate that IL-5 and eosinophils are cen- 
tral mediators in the pathogenesis of allergic lung disease. 
C 
haracterization of the cellular and chemical events of 
asthma suggests  that inflammatory cells play a central 
role in the clinical expression and pathogenesis of the dis- 
ease (1). Clinical investigations show a correlation between 
the  presence  of activated  inflammatory  cells,  histological 
changes to pulmonary tissue,  and the development of air- 
ways hyperreactivity (2-5). The cellular composition of the 
inflammatory  infiltrate  in  the  lung  is  characterized  by 
increased numbers of activated neutrophils, mast cells,  eo- 
sinophils,  and  monocytes,  and  the  recruitment  and/or 
activation of these cells appears to be controlled by the se- 
cretion of cytokines and chemotactic agents from antigen- 
stimulated T lymphocytes (4-8). After accumulation at sites 
of allergic  inflammation,  these  inflammatory cells  release 
mediators  (e.g.,  platelet-activating  factor,  leukotrienes, 
prostaglandins, histamine, cytokines, chemokines, and cat- 
ionic proteins) that have the potential to augment the in- 
flammatory response  and  induce  tissue  damage  and  dys- 
function (1). 
In  asthma,  airways limitation may be induced by IgE- 
dependent release of spasmogenic mediators from activated 
mast cells (9,  10). Similarly, eosinophils and neutrophils, by 
releasing  granular  proteins,  lipid  mediators,  and  oxygen 
metabolites,  also  have  the  potential to  induce pulmonary 
damage and airways hyperreactivity and to exacerbate the 
inflammatory response (10-13). Whereas these cells and the 
mediators they release may contribute to a complex inflam- 
matory cascade, their individual roles in the events that ini- 
tiate the morphological and functional changes of the asth- 
matic lung are unknown. 
Recently,  there has  been increasing interest in  the  in- 
volvement  of eosinophils  in  the  pathogenesis  of asthma 
(14).  In the majority of clinical studies, pulmonary eosino- 
philia has been recognized as a predominant feature of the 
inflammatory infiltrate, which often correlates with disease 
severity (2-5,  14).  A  number  of inflammatory mediators 
(platelet-activating factor, leukotriene B4, IL-5, and chemo- 
kines [RANTES, macrophage chemoattractant protein, mac- 
rophage  inflammatory protein,  and  eotaxin])  have  chemo- 
tactic  activity for  eosinophils  and  are  candidates  for  the 
control of eosinophflia in asthma (15-18). Of these media- 
toes, only IL-5 regulates the growth, differentiation, and acti- 
vation of eosinophils (19-21). 
Furthermore, activated CD4 + Th2-type cells, which can 
produce IL-5 and several other cytokines, are activated in a 
greater proportion in asthmatic individuals (6-8,  13). Ele- 
vated levels of IL-5 and cells  expressing mRNA  for IL-5 
are also found in the blood and lung secretions from asth- 
matic  patients  or  after  allergen-induced  late-phase  asth- 
matic  responses and  correlate with  the  degree of eosino- 
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of investigations  to  date,  IL-5  production  by  activated  T 
lymphocytes and pulmonary eosinophilia have been associ- 
ated with  asthma.  However,  a  number of other cytokines 
are also produced by activated T  lymphocytes, and eosino- 
phils are  only one of a number of inflammatory cell types 
regularly found in  the  pulmonary infiltrates  in  asthma.  In 
animal  studies,  mAbs  directed  against  IL-5  have  been 
shown to suppress, but not abolish, pulmonary eosinophilia 
in response to antigen challenge, and the correlation of this 
effect with changes in lung morphology or airways hyper- 
reactivity remains controversial (23, 24). Furthermore,  evi- 
dence for the role of eosinophils in the development of air- 
ways hyperreactivity is conflicting (3, 4, 23, 25, 26). 
In this work we have tried  to gain evidence of the rela- 
tive importance of IL-5 and eosinophils in the pathogenesis 
of asthma by using a mouse  asthma  model  and  IL-5-defi- 
cient  (IL-5-)  mice  (26a).  We  have  established  a  mouse 
model of allergic pulmonary inflammation that mimics  al- 
lergen-induced  late-phase  asthmatic  responses.  In  this 
model,  aeroallergen  challenge  of sensitized  mice results  in 
airways  hyperreactivity  to  [3-methacholine  (this  airways 
spasmogen is used widely as a clinical tool to assess disease 
severity  in  asthmatic  patients),  severe  pulmonary  eosino- 
philic inflammation,  and changes in lung morphology that 
closely parallel those observed in the asthmatic lung (1,  3). 
We  have  used  the  mouse  model  of allergic  inflammation 
and IL-5- mice  (which completely lack this  cytokine) as a 
novel way of gaining unequivocal data concerning the role 
of IL-5 in pulmonary eosinophilia and the development of 
Figure  1.  Histological analysis of lung sections. (a) 
IL-5  + mice that were not sensitized and were exposed 
to an aerosol of  saline (nonsensitized IL-5- not shown). 
(b and c) Sensitized IL-5  + mice exposed to aerosolized 
OVA. (d and e) Sensitized IL-5- mice exposed to aero- 
solized OVA. Sections shown are representative of 10 
sections of lung per  mouse from five mice in  each 
group. Lung tissue was stained with May-Grunwald- 
Giemsa solution (a,  b,  d,  and e)  or hematoxylin and 
eosin (c). X109 (a, b); ￿  (c); X53.5 (d); ￿  (e). 
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Figure 2.  Eosinophil numbers in (a) 
blood and (b) BALF, (c) inflammatory 
cell numbers  in BALL and  (d)  serum 
OVA-specific IgE levels in nonsensi- 
tized  and  aeroallergen-challenged, 
sensitized IL-5  + and IL-5- mice. Data 
represent the mean +  SEM for groups 
of four or five mice.  The significance 
of differences  between  experimental 
groups  was  analyzed  using  the  un- 
paired  Student's  t  test.  Differences 
were considered significant if P <0.05. 
(a)  *P <0.001  compared  with day 30 
IL-5 + OVA.  (b)  *P <0.01  compared 
with IL-5 + OVA.  Eosinophil levels in 
the blood  were determined  from days 
24-32 as indicated. All other data were 
obtained at day" 30. 
aeroallergen-induced  lung  damage  and  airways  hyperreac- 
tivity in vivo.  In  IL-5-  mice,  the  airways  hyperreactivity, 
eosinophilia,  and  gross  changes  in  pulmonary  structure 
normally  resulting from  aeroallergen  challenge were  abol- 
ished, providing clear evidence of the central importance of 
IL-5  and  eosinophils  in aeroallergen-induced  lung damage 
and airways hyperreactivity. 
Materials  and Methods 
Aeroallergen Treatment of Mice.  Mice  (C57BL/6,  6-10  wk of 
age) were sensitized by i.p. injection with 50 ~g OVA/1 mg A1- 
hydrogel (CSL Ltd., Parkville, Australia) in 0.9% sterile saline on 
days 0  and  12.  Nonsensitized mice received 1 mg of Alhydrogel 
in 0.9% saline.  On day 24,  the appropriate  groups of mice were 
exposed to an aerosol of OVA (10 mg/ml) in 0.9% saline (non- 
sensitized mice received saline only) for 30 rain three times (at 1-h 
intervals),  and  then  every  second  day  thereafter,  for  8  d.  The 
aerosol was generated at 6 liters/rain by a nebulizer that produced 
a mean particle diameter of 3.9 ~m into a dosed chamber of 800 
cm  3. 3 h after the last aeroallergen challenge, mice were killed by 
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cervical  dislocation,  or  airways  hyperreactivity  was  measured. 
Lung responses of IL-5- mice were compared with control litter 
mates  (IL-5+),  which  were  simultaneously  treated.  Mice  were 
treated according to Australian National University Animal Wel- 
fare guidelines and were housed in an approved containment fa- 
cility. 
Measurement of Airways Hyperreactivity.  Mice were anesthetized 
with ketamine (60 mg/kg) and rompun (8 mg/kg) by intraperito- 
neal  injection,  and  their  trachea  and  tail vein were  cannulated. 
The  tracheal cannula was  then connected to a rodent ventilator 
and  a  bronchospasm  transducer  (Ugo  Basil  7020),  which  was 
coupled to a Lab Mac/8 analysis  station (Adlnstruments,  Sydney, 
Australia). Mice were mechanically ventilated at 60 strokes/min, 
with a stroke volume of 1 rnl after neuromuscular blockade with 
0.5  mg/kg suxamethonium.  Airways constriction  was measured 
by  determining  changes  in  respiratory  overflow volume during 
cumulative  intravenous  administration  of [3-methacholine.  The 
increase  in  respiratory  overflow volume provoked by ~-metha- 
choline is  represented  as  a  percentage  of the maximal  overflow 
volume  (100%)  obtained  by  totally occluding the  tracheal  can- 
nula.  To  avoid an  anesthesia-induced  fall in body  temperature, 
ambient temperature was maintained at 30~ 80' 
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Figure  3.  Measurement  of airways reactivity  to  l~-methacholine  in 
nonsensitized and aeroaUergen-challenged (OVA), sensitized IL-5 §  and 
IL-5- mice. Airways constriction was measured by determining changes 
in respiratory overflow volume during cumulative intravenous adminis- 
tration of ~-methacholine and is represented as a percentage of the maxi- 
mal overflow volume (100%) obtained by totally occluding the tracheal 
cannula. Data represent the mean -+  SEM for groups of five to seven 
mice. The significance of differences between experimental groups was 
analyzed using the unpaired Student's t test. Differences were considered 
significant if P <0.05. (a) *P <0.001 compared with responses of IL-5 + 
OVA. (b) *P <0.001 compared with IL-5  OVA. 
Histology.  Lung tissue representing the central (bronchi-bron- 
chiole)  and peripheral  (alveoli) airways was  fixed in 10% phos- 
phate-buffered formalin, sectioned, and stained with May-Grun- 
wald-Giemsa solution or hematoxylin and eosin. 
Collection and Analysis of Peripheral Blood and Bronchoalveolar Lav- 
age  Fluid.  Tracheae  were  cannulated and  the  airways  lumina 
were washed with 4 ￿  1 ml of 0.9% saline containing BSA (0.1% 
wt/vol) at 37~  Approximately 0.8 ml of the instilled fluid was 
recovered  per wash.  The  bronchoalveolar lavage fluid (BALF) 1 
obtained from one animal was pooled and centrifuged (150 g) at 
4~  for 10 rain. Cell numbers were determined using a standard 
hemocytometer.  BALF  cells  were  resuspended  in  lymphocyte 
culture medium (100 txl), cytocentrifuged at 500 rpm for 5 rain, 
and differentially stained with May-Gmnwald-Giemsa solution. 
Cell types were identified using morphological criteria. 200-300 
leukocytes  were  counted  on  each  slide.  Blood  samples  were 
drawn from the tail vein for differential cell counts. 
Measurements of Serum IgE.  Serum OVA-specific IgE was de- 
tected by isotype-specific ELISA using rat anti-mouse IgE mAb, 
clone LO-ME-3 (Biosource International, Camarillo, CA). OVA- 
specific  IgE  was  quantified against standard mouse  IgE.  OVA- 
specific IgE was detected only at background levels (<10 ng) in 
unimmunized mice. 
rVV  Inoculation.  rVV  were  constructed  as  described  (27). 
Mice were given intranasal inocula of 107 PFU of VV-HA-TK or 
VV-HA-IL-5 in 20 txl saline under light ether anesthesia on days 
24 and 28 after OVA sensitization. Virus growth in the lungs of 
mice given intranasal inocula of VV-HA-IL-5 or VV-HA-TK is 
sustained at similar levels over 6 d and is maximal at days 2-3. On 
day 30 after the last OVA aerosolization, lungs were removed for 
histological analysis. 
1Abbreviations used in this paper: BALF, bronchoalveolar lavage fluid; rW, 
recombinant vaccinia virus. 
Results and Discussion 
Characterization  of Allergic  Airways  Inflammation  in  Mice. 
Aerosol challenge of mice with OVA induced a significant 
increase in eosinophils in the lung (Fig.  1 b), blood (Fig. 2 
a), and BALF (Fig. 2  b), in comparison to mice given aero- 
solized  saline  (Figs.  1  and  2).  Eosinophilic  inflammation 
was widespread, with dense cellular peribronchial and peri- 
vascular infiltration (Fig.  1,  b and c).  Infiltration of pulmo- 
nary lymphocytes and neutrophils was also significantly ele- 
vated  (Fig.  2  c).  Lung  tissue  in  mice  given  OVA  was 
characterized by gross alterations in the structural integrity 
of the  airway  walls  (bronchi  and  broncheoli)  and  paren- 
chyma,  epithelial cell shedding,  microvascular leakage and 
extensive  mucosal  edema,  increased  tissue  cellularity,  and 
particulate  exudates  in  the  airways  lumina  and  alveolar 
septa  (Fig.  1,  b and c).  In some  animals, thickening of the 
epithelial basement membrane region and alterations in the 
integrity  of the  smooth  muscle  band  were  also  observed 
(results not shown). Aeroallergen-induced pulmonary dam- 
age was directly associated with the induction of airways hy- 
perreactivity to 13-methacholine (Fig. 3). 
The  Role  of IL-5  in  Pulmonary  Eosinophilia  and Airways 
Dysfunction.  The  role  of IL-5  in the  selective  accumula- 
tion of eosinophils and the development of pulmonary dys- 
function was analyzed in IL-5- mice using the aeroallergen- 
induced lung damage  model.  IL-5-  mice  are  specifically 
affected in IL-5 production, with no evidence of secondary 
effects on other cytokines or antibody production (26a).  In 
marked contrast to the results with IL-5 + mice, OVA aero- 
solization of sensitized IL-5-  mice of the  C57BL/6  back- 
ground induced no airways or blood eosinophilia (Fig. 2, a 
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Figure 4.  Eosinophil levels in peripheral blood from sensitized IL-5- 
mice infected with VV-HA-TK or VV-HA-IL-5 and exposed to aero- 
solized OVA. Data represent the mean -+ SEM for groups of four mice. 
The significance of differences between experimental groups was analyzed 
using the unpaired Student's t test. Differences were considered significant 
ifP <0.05. *P <0.01 compared with day 30 IL-5  OVA plus VV-HA- 
IL-5. Mice were  inoculated  with rVV, and levels of blood eosinophils 
were analyzed as described in Materials and Methods. 
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structure  (Fig.  1,  d  and  e).  Lung histology and  eosinophil 
numbers  in BALF and blood taken from these  animals  re- 
sembled  those  of mice  that  were  not  actively  sensitized 
(Figs.  1 a and 2,  a and b).  In contrast, neutrophil and lym- 
phocyte numbers in BALF were significantly elevated after 
aeroallergen challenge of IL-5- mice, although increases in 
the latter were  less  marked  than  in  IL-5 +  mice  (Fig.  2  c). 
OVA-specific IgE was detected at similar levels in sera from 
IL-5 +  and  IL-5-  mice  after aeroallergen  challenge  (Fig.  2 
at), indicating  that  IgE  and  eosinophilia  are  independently 
regulated, as previously shown in pulmonary parasitic infes- 
tation  (28)  and  allergic  bronchopulmonary  aspergillosis 
(29).  Airways  hyperreactivity to  [3-methacholine  was  also 
abolished  in  aeroallergen-challenged  IL-5-  mice  (Fig.  3). 
These results establish that IL-S plays a pivotal role in gen- 
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Figure  5.  Histological analysis of lung sections from IL-5  mice given 
(a-c) VV-HA-IL-5 and aerosolized OVA and (d) W-HA-IL-5 only. Sec- 
tions shown are representative of 10 sections of lung per mouse from five 
mice in each group. Mice were given intranasal inocula (days 24 and 28 
after OVA challenge), and on day 30 after the last OVA aerosolization, 
lungs were removed for histological analysis as described in Materials and 
Methods. Sections were stained with May-Grunwald-Giemsa solution (a, 
b, and d) or hematoxylin and eosin (c). ￿  (a); ￿  (b); ￿  (c-d). IL-5" VV-HA-1L-5 
￿9  1L-5- Ova VV-HA-IL-5 
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Figure  6.  Measurement of airways reactivity to  [3-methacholine in 
aeroallergen-challenged (OVA), sensitized IL-5  mice  after reconstituting 
IL-5 production with VV-HA-IL=5.  Airways constriction was measured 
by determining changes in respiratory overflow volume as described in 
Fig. 3. Data represent the mean + SEM for groups of three to five mice. 
The significance of  differences between experimental groups was analyzed 
using the unpaired Student's t test. Differences were considered significant 
if P <0.05. *P <0.05 and **P <0.01 compared with responses of IL-5- 
VV-HA-IL-5. 
erating the observed blood and airways eosinophilia and in 
the subsequent development of airways hyperreactivity and 
lung  damage,  which  occurs  in  response  to  aeroallergens. 
These data also indicate that eosinophils are the proinflam- 
matory cells primarily involved in the induction of changes 
in  pulmonary structure  and  function.  Histological  analysis 
showed no increase in mast cell numbers after sensitization 
and aeroallergen challenge of IL-5  §  or IL-5- mice (results 
not  shown),  supporting previous  evidence  obtained  from 
mast cell-deficient mice that this cell is not required for the 
induction  of chronic  airways  inflammation  in  this  model 
(30). 
Restoration of AeroaUergen-induced Eosinophilia and Airways 
Dysfunction in IL-5-Mice.  The  central  role  of  IL-5  in 
aeroallergen-induced eosinophilic recruitment into the air- 
ways was confirmed by resconstituting  IL-5 production in 
the lungs of IL-5- mice by using a rVV expressing this fac- 
tor (VV=HA=IL-5) (27). An appropriate control virus with= 
out IL-5 (VV-HA-TK) was also used (27).  rVV constructs 
encoding  cytokine  genes  deliver  these  factors  in  a  highly 
localized manner. The encoded cytokines are secreted from 
infected cells  in amounts determined by the extent of viral 
replication,  and have been shown to influence specific im- 
mune responses  (27, 3l).  In the lungs of IL-5- mice,  VV- 
HA-IL-5  and  VV-HA-TK  localized  in  the  parenchyma 
and foci of infected cells  are established  with similar tissue 
tropisms.  The  lungs  of sensitized  IL-5-  mice  exposed  to 
the  control  virus  VV-HA-TK  showed  highly  localized 
pockets of airways inflammation,  which were not charac- 
terized by eosinophilic  infiltration  (results  not shown)  and 
which correlated with sites  of virus infection. Exposure of 
these mice to aerosolized OVA did not induce further air- 
ways inflammation or lung damage. However, blood eosin- 
ophilia  (Fig.  4),  severe  pulmonary eosinophilic  inflamma- 
tion  and  characteristic  lung  pathology  (Fig.  5,  a--c), and 
airways  hyperreactivity  (Fig.  6)  were  restored  in  IL-5- 
mice challenged with aerosolized OVA and given VV-HA- 
IL-5. The lungs of IL-5- mice given VV=HA-IL-5 in the 
absence  of OVA  sensitization  and  aerosolization  showed 
some evidence of eosinophil migration,  which was prima- 
rily localized to the sites  of rVV infection but was not ac- 
companied by dense cellular infiltration or changes in lung 
morphology (Fig.  5  at). It will be of interest  to determine 
what factors derived from the site of OVA presentation are 
involved in  the  amplification  of the  signal  for eosinophil 
migration and are essential  for widespread eosinophilic  in- 
flammation and degranulation and the onset of pulmonary 
dysfunction. Recently, after stimulation with IgA, IgG, or 
IgE  immune  complexes,  eosinophils  were  shown  to  de- 
granulate and secrete significant amounts of IL-5 (32). The 
synthesis and secretion of IL-5 and other activating factors 
from eosinophils may provide an important autocrine path- 
way  that  regulates  localized  eosinophil  accumulation  and 
activation, and that modulates the inflammatory process. 
We conclude that IL-5 is essential  for mounting aeroaller- 
gen-induced pulmonary and blood eosinophilia,  as well as 
the  subsequent  onset  of airways  hyperreactivity  and  lung 
damage  in  vivo.  Our  findings  in  a  mouse  asthma  model 
strongly support clinical investigations that suggest that IL-5 
is an important target for improved asthma therapy. 
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